2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)
09 December - 11 December, 2025, Singapore
Inhaled Technosphere insulin significantly reduced HbA1c levels in Indian individuals with type 2 diabetes (T2D) compared with placebo, according to a study presented at ATTD-ASIA 2025.
Treatment with iGlarLixi* resulted in better clinical outcomes than IDegAsp** in Chinese adults with type 2 diabetes (T2D), regardless of age or disease duration at baseline, according to a post hoc analysis of the phase III Soli-D study presented at ATTD-ASIA 2025.
